Literature DB >> 26622607

Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report.

Sachi Morita1, Mariko Hiramatsu2, Mihoko Sugishita1, Bishal Gyawali1, Takashi Shibata1, Tomoya Shimokata1, Hiroshi Urakawa1, Ayako Mitsuma1, Suzuko Moritani3, Toshinobu Kubota4, Shu Ichihara3, Yuichi Ando1.   

Abstract

Granular cell tumors are uncommon, usually benign tumors of Schwann cell origin. The malignant variant is extremely rare, representing <2% of all granular cell tumors. Therefore, standard systemic chemotherapy for this disease does not exist. The present study reports the case of a 40-year-old female with a malignant granular cell tumor that originally arose in the right orbit and subsequently relapsed. The patient was started on pazopanib monotherapy following treatment with two investigational drugs, a smoothened inhibitor and then a phosphatidylinositol 3-kinase inhibitor, as part of a clinical trial. Although additional radiotherapy for local control was necessary, the lung metastases remained stable during the pazopanib monotherapy, which lasted for 7 months, following which a clinically stable disease state was determined. This case suggests that pazopanib can be a treatment option for the stabilization of disease progression in metastatic malignant granular cell tumor.

Entities:  

Keywords:  malignant granular cell tumor; orbit; pazopanib

Year:  2015        PMID: 26622607      PMCID: PMC4509081          DOI: 10.3892/ol.2015.3263

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  8 in total

1.  Granular cell myoblastoma--a misnomer. Electron microscopic and histochemical evidence concerning its Schwann cell derivation and nature (granular cell schwannoma).

Authors:  E R FISHER; H WECHSLER
Journal:  Cancer       Date:  1962 Sep-Oct       Impact factor: 6.860

2.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

3.  Gemcitabine plus paclitaxel may be a promising chemotherapy regimen for metastatic granular cell tumour.

Authors:  O Kanat; U Yalcinkaya; T Akbunar; E Kurt; T Evrensel; O Manavoglu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-10-22       Impact factor: 4.126

4.  Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor.

Authors:  Anthony P Conley; Stephanie Koplin; Jamie T Caracciollo; Damon R Reed; Nicolas P Webber; Steven Attia
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

5.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

6.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Authors:  Stefan Sleijfer; Isabelle Ray-Coquard; Zsuzsa Papai; Axel Le Cesne; Michelle Scurr; Patrick Schöffski; Françoise Collin; Lini Pandite; Sandrine Marreaud; Annick De Brauwer; Martine van Glabbeke; Jaap Verweij; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation.

Authors:  J C Fanburg-Smith; J M Meis-Kindblom; R Fante; L G Kindblom
Journal:  Am J Surg Pathol       Date:  1998-07       Impact factor: 6.394

Review 8.  Functional and cancer genomics of ASXL family members.

Authors:  M Katoh
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

  8 in total
  5 in total

1.  Intraorbital Granular Cell Tumor Involving in Medial Rectus and Optic Nerve.

Authors:  Guo-Yuan Yang; Wei-Min He
Journal:  Chin Med J (Engl)       Date:  2017-07-05       Impact factor: 2.628

2.  Recurrent Unresectable Malignant Granular Cell Tumor With Response to Pazopanib.

Authors:  Vatsala Katiyar; Ishaan Vohra; Alok Uprety; Wei Yin; Shweta Gupta
Journal:  Cureus       Date:  2020-05-26

3.  Retinal granular cell tumor: a case report.

Authors:  Jimin Park; Kyung-Ja Cho; Junyeop Lee
Journal:  BMC Ophthalmol       Date:  2021-12-27       Impact factor: 2.209

4.  Aggressive oral granular cell tumor with periorbital involvement: An unusual case.

Authors:  Rajiv Garg; Gunjan Rana; Siddharth Madan; Anita Nangia; Rekha Yadav
Journal:  J Indian Soc Periodontol       Date:  2021-11-01

5.  Colonic granular cell tumor: Report of 11 cases and management with review of the literature.

Authors:  Yahua Chen; Yangyang Chen; Xiaoqiong Chen; Liang Chen; Wei Liang
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.